Hunt for innovation spurs J&J to expand life science startup workspace

9:41 am by | 1 Comments

Janssen Labs, La Jolla, CAOne approach pharmaceutical companies have been taking to replenish their drug development pipelines is not only investing in early stage biotechnology companies, but also opening innovation centers to help these companies grow. A year after Johnson & Johnson’s (NYSE: JNJ) pharmaceutical division Janssen opened its innovation center for life science startups in San Diego, it has added additional space to provide more flexibility for new companies.

Janssen Labs‘ “concept lab” is a shared laboratory that gives entrepreneurs access to lab space without having to commit to additional capital. A new open collaboration space has an open plan layout to spark interaction between life science entrepreneurs. It can accommodate enough people to expand the number of companies Janssen Labs houses from 18 to 30. The total space is 32,000 square feet.

Companies that successfully apply to work in the space do not automatically give Janssen a stake in their business. On the other hand, Janssen doesn’t guarantee future affiliation with the companies either. But it’s a useful place to start that conversation if either side wants it.

The space is set up to be flexible because early stage life science companies, like other startups, can be leery about longterm commitments to real estate since the road ahead of them is chock full of unexpected developments, good and bad. Companies rent the space and modular wet lab units on a short term renewable basis and only pay for the space that they need. They also can expand when they have the ability to do that.


Janssen Labs is part of a wider effort by J&J to enlist creative deal making strategies , to position itself to spot  opportunities early. It also helps make the medical device and big pharma business appear more welcoming to innovation and early stage companies, who face the daunting challenge of convincing private investors and companies to invest in their business.

In September, J&J said it would open innovation centers in Boston, China and Europe, staffed with J&J science and technology experts from each community who will identify early stage innovations. They are also tasked with establishing collaborations to invest in and speed development of those concepts to solve unmet needs in patients.

Copyright 2015 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Stephanie Baum

By Stephanie Baum

Stephanie Baum is the East Coast Innovation Reporter for She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.
Visit website | More posts by Author


Great article, the start-up game can be a very stressful yet rewarding road to those who not only understand their perspective industry but also the consistent effort it takes to make one successful. With the cutbacks from some device manufacturers due to excise tax it will be interesting to see if new start-ups are able to continue finding funding. With Johnson and Johnson having a market cap twice that of Bank of Americas it should not be to much of an issue for them.


Jonathan George

Pacific Medical LLC 

Sales and Marketing